2022
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Nguyen N, Luo J, Paul P, Kim J, Syal G, Ha C, Rudrapatna V, Park S, Parekh N, Zheng K, Sauk J, Limketkai B, Fleshner P, Eisenstein S, Ramamoorthy S, Melmed G, Dulai P, Boland B, Mahadevan U, Sandborn W, Ohno-Machado L, McGovern D, Singh S. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Clinical Gastroenterology And Hepatology 2022, 21: 173-181.e5. PMID: 35644340, PMCID: PMC9701245, DOI: 10.1016/j.cgh.2022.05.008.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseNon-Hispanic patientsBiologic-treated patientsHispanic patientsSerious infectionsBiologic therapyBowel diseasePropensity score-matched cohortBurden of inflammationRisk of hospitalizationHigh ratePropensity-score matchingCause hospitalizationAdult patientsBiologic initiationCohort studyBiologic agentsMedication useHigh burdenHigh riskHospitalizationPatientsSurvival analysisSurgeryAbstractText
2020
Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures
Resnic F, Majithia A, Dhruva S, Ssemaganda H, Robbins S, Marinac-Dabic D, Hewitt K, Ohno-Machado L, Reynolds M, Matheny M. Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006105. PMID: 32283971, PMCID: PMC7360169, DOI: 10.1161/circoutcomes.119.006105.Peer-Reviewed Original ResearchConceptsICD RegistryLead failureActive surveillanceNational Cardiovascular Data Registry ICD RegistryImplantable Cardioverter-Defibrillator RegistryPrimary safety end pointPropensity-matched survival analysisRate of freedomSafety end pointLead failure rateLong-term safetySignificant patient harmDefibrillator lead failureEarly lead failureMonitoring of safetyComparator patientsContemporary ICDLead survivalMeaningful differencesOutcome ascertainmentFailure rateNew ICDPatient harmPatientsSurvival analysis